Patents by Inventor Jean-Pierre Sommadossi

Jean-Pierre Sommadossi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ?-D-2?-deoxy-2?-?-fluoro-2?-?-C-substituted-2-modified-N-substituted purine nucleotides for HCV treatment
    Patent number: 9828410
    Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: November 28, 2017
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS
    Publication number: 20170088577
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Application
    Filed: December 14, 2016
    Publication date: March 30, 2017
    Inventors: Richard STORER, Gilles GOSSELIN, Jean-Pierre SOMMADOSSI, Paolo LACOLLA
  • Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
    Publication number: 20160257706
    Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 8, 2016
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • 2'-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION
    Publication number: 20160166597
    Abstract: The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2?-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 16, 2016
    Inventors: Jean-Pierre SOMMADOSSI, Paolo LACOLLA, David N. STANDRING, Vadim BICHKO, Lin QU
  • Compounds and pharmaceutical compositions for the treatment of viral infections
    Patent number: 9249173
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: February 2, 2016
    Assignee: Idenix Pharmaceuticals, LLC
    Inventors: Jean-Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
  • MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS
    Publication number: 20150017124
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 15, 2015
    Inventors: Richard STORER, Gilles GOSSELIN, Jean-Pierre SOMMADOSSI, Paolo LACOLLA
  • 2'-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION
    Publication number: 20140286900
    Abstract: The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2?-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.
    Type: Application
    Filed: February 18, 2014
    Publication date: September 25, 2014
    Applicant: Idenix Pharmaceuticals, Inc.
    Inventors: Jean-Pierre SOMMADOSSI, Paolo LACOLLA, David N. STANDRING, Vadim BICHKO, Lin QU
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
    Publication number: 20140255339
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicants: Idenix Pharmaceuticals, Inc., Universite Montpellier II, Centre National de la Recherche Scientifique
    Inventors: Jean-Pierre SOMMADOSSI, Gilles GOSSELIN, Claire PIERRA, Christian PERIGAUD, Suzanne PEYROTTES
  • MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS
    Publication number: 20140213540
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Application
    Filed: March 20, 2014
    Publication date: July 31, 2014
    Applicants: IDENIX PHARMACEUTICALS, INC., L'UNIVERSITE MONTPELLIER II, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITA DEGLI STUDI DI CAGLIARI
    Inventors: Richard STORER, Gilles GOSSELIN, Jean-Pierre SOMMADOSSI, Paolo LACOLLA
  • MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS
    Publication number: 20140113880
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Application
    Filed: January 2, 2014
    Publication date: April 24, 2014
    Applicants: Idenix Pharmaceuticals, Inc., L'Universite Montpellier II, Centre National de la Recherche Scientiflque, Universita degli Studi di Cagliari
    Inventors: Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi, Paolo LaColla
  • Compounds and pharmaceutical compositions for the treatment of viral infections
    Patent number: 8691788
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: April 8, 2014
    Assignees: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, Universite Montpellier II
    Inventors: Jean-Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
  • 2?-branched nucleosides and mutation
    Patent number: 8674085
    Abstract: The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2?-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: March 18, 2014
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paolo LaColla, David N. Standring, Vadim Bichko, Lin Qu
  • Modified 2? and 3? nucleoside prodrugs for treating flaviviridae infections
    Patent number: 8637475
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: January 28, 2014
    Assignees: Idenix Pharmaceuticals, Inc., University of Cagliari, The Centre National de la Recherché Scientifique, L'Universite Montpelier II
    Inventors: Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi
  • MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS
    Publication number: 20130330297
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Application
    Filed: August 2, 2013
    Publication date: December 12, 2013
    Applicants: Idenix Pharmaceuticals, Inc., L'Universite Montpellier II (UMII), Centre National De La Recherche Scientifique (CNRS), Universita degli Studi di Cagliari
    Inventors: Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi, Paolo LaColla
  • METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE INFECTIONS
    Publication number: 20130315863
    Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: July 31, 2013
    Publication date: November 28, 2013
    Applicants: Universita' degli Studi di Cagliari, Idenix Pharmaceuticals, Inc.
    Inventors: Jean-Pierre SOMMADOSSI, Paolo LaColla
  • METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS
    Publication number: 20130315862
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: July 29, 2013
    Publication date: November 28, 2013
    Applicants: Universita' degli Studi di Cagliari, Idenix Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Paolo LaColla
  • METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES
    Publication number: 20130310336
    Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: November 13, 2012
    Publication date: November 21, 2013
    Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.
    Inventors: Jean-Pierre SOMMADOSSI, Paolo LACOLLA
  • Methods and compositions for treating flaviviruses and pestiviruses
    Patent number: 8343937
    Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: January 1, 2013
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paulo LaColla
  • Methods and compositions for treating hepatitis C virus
    Patent number: 8299038
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: October 30, 2012
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paulo LaColla
  • ?-L-2?-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
    Patent number: 8158606
    Abstract: It has been discovered that ?-L-2?-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a ?-L-2?-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a ?-L-2?-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a ?-L-2?-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: April 17, 2012
    Assignee: Novartis, AG
    Inventors: David Standring, Jean-Pierre Sommadossi, April Patty, Maria Seifer